Expertise in developing oral drug formulations for cancer therapies

With our dedication to improving the delivery and bioavailability of chemotherapy, we are open to discussing partnering opportunities either relating to our proprietary programs in clinical development or to our IV-to-oral technology.


From a corporate development perspective, we are well-positioned to collaborate with international pharmaceutical leaders, innovative early-staged companies, academic institutions and other research organizations to apply our proprietary technology to make a positive impact for cancer patients.



Phase I results with ModraDoc006/r published in the European Journal of Cancer
Read more

the IV to Oral switch

improving patient lives
Learn more


Meet us at one of the following events:      
Read more